Clinical trial · Observational
A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
Clinical Study on the Accuracy of Novel Serological Risk Model in Early Diagnosis of Cholangiocarcinoma Patients
NCT06658587CI-TRIAL-00081949not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of a novel serological risk model on blood samples in early diagnosis of cholangiocarcinoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No interventions | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Sun Yat-Sen Memorial Hospital of Sun Yat-sen University
- description
- The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
- interventionNames
- Diagnostic Test: No interventions
Primary outcomes (2)
- measure
- Malignant/Benign status of enrolled suspected cholangiocarcinoma patients by pathological examination
- timeFrame
- 4 weeks
- description
- The pathological examination results of each enrolled patient will be recorded
- measure
- Malignant/Benign status of enrolled suspected cholangiocarcinoma patients evaluated by the novel serological risk model
- timeFrame
- 2 weeks
- description
- The novel serological risk model will be constructed for differential malignant/benign diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. The patient must sign an informed consent form; * 2\. Age 18-75 years old, both male and female; * 3\. ECOG performance status score (PS score) 0-2; * 4\. Cholangiocarcinoma with resectable tumor lesions; * 5\. Complete the blood collection before treatment; Exclusion Criteria: * 1\. Accompanied with other primary malignant tumors; * 2\. Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies; * 3\. Incomplete serological examinations or medical history data.
References
Publications (0)
Data not yet available
No reference posted for this study.